Replies to post #214545 on Biotech Values

[semi_infinite]

thx. I find it curious that the FDA cleared the MR system (Perspectum) for early liver disease imaging with minimal biopsy supporting data. That's the implication because the trial to collect biopsy data to support imaging results is not to be completed for another 3 years. There had to be some biopsy data?

https://clinicaltrials.gov/ct2/show/NCT03165201